ESMO - European Society for Medical Oncology
@myesmo.bsky.social
The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.
ML& DL models can predict DFS and OS after neoadjuvant chemotherapy in HR+/HER2- #BreastCancer using routine data. A study suggests interpretable models may perform well without complex data.
Read the commentary by Rodrigo Dienstmann
#HealthAI #ESMODailyReporter 🔗 https://ow.ly/H9xQ50XN2Nh
Read the commentary by Rodrigo Dienstmann
#HealthAI #ESMODailyReporter 🔗 https://ow.ly/H9xQ50XN2Nh
December 22, 2025 at 3:20 PM
ML& DL models can predict DFS and OS after neoadjuvant chemotherapy in HR+/HER2- #BreastCancer using routine data. A study suggests interpretable models may perform well without complex data.
Read the commentary by Rodrigo Dienstmann
#HealthAI #ESMODailyReporter 🔗 https://ow.ly/H9xQ50XN2Nh
Read the commentary by Rodrigo Dienstmann
#HealthAI #ESMODailyReporter 🔗 https://ow.ly/H9xQ50XN2Nh
👉 #ELCC26 unites every discipline in #ThoracicOncology. Intimate yet truly global. In this clip, Natasha Leighl explains why that mix matters and why ELCC is a global meeting to reach a broader audience
🔗 Submit your abstract: buff.ly/99EQAgt
⏰ 13 Jan 2026 (21:00 CET)
🔗 Submit your abstract: buff.ly/99EQAgt
⏰ 13 Jan 2026 (21:00 CET)
December 22, 2025 at 8:45 AM
👉 #ELCC26 unites every discipline in #ThoracicOncology. Intimate yet truly global. In this clip, Natasha Leighl explains why that mix matters and why ELCC is a global meeting to reach a broader audience
🔗 Submit your abstract: buff.ly/99EQAgt
⏰ 13 Jan 2026 (21:00 CET)
🔗 Submit your abstract: buff.ly/99EQAgt
⏰ 13 Jan 2026 (21:00 CET)
In the #ESMODailyReporter, Umberto Malapelle explains how concomitant analysis of DNA and RNA can advance cancer characterisation and guide clinical decision making, highlighting data presented at #ESMOAsia25
📌 https://ow.ly/bGI350XM8f6
#PrecisionOncology
📌 https://ow.ly/bGI350XM8f6
#PrecisionOncology
December 19, 2025 at 10:30 AM
In the #ESMODailyReporter, Umberto Malapelle explains how concomitant analysis of DNA and RNA can advance cancer characterisation and guide clinical decision making, highlighting data presented at #ESMOAsia25
📌 https://ow.ly/bGI350XM8f6
#PrecisionOncology
📌 https://ow.ly/bGI350XM8f6
#PrecisionOncology
📣 #ELCC26: Your new data deserves a global platform
Submit your abstract now 🔗 buff.ly/a44FfwT
@drjnaidoo.bsky.social addresses the community, underscoring the value of contributing to shared progress in #ThoracicOncology
⏰ 13 Jan 2026 (21:00 CET)
Submit your abstract now 🔗 buff.ly/a44FfwT
@drjnaidoo.bsky.social addresses the community, underscoring the value of contributing to shared progress in #ThoracicOncology
⏰ 13 Jan 2026 (21:00 CET)
December 19, 2025 at 8:31 AM
📣 #ELCC26: Your new data deserves a global platform
Submit your abstract now 🔗 buff.ly/a44FfwT
@drjnaidoo.bsky.social addresses the community, underscoring the value of contributing to shared progress in #ThoracicOncology
⏰ 13 Jan 2026 (21:00 CET)
Submit your abstract now 🔗 buff.ly/a44FfwT
@drjnaidoo.bsky.social addresses the community, underscoring the value of contributing to shared progress in #ThoracicOncology
⏰ 13 Jan 2026 (21:00 CET)
📣 Updated ESMO #ClinicalPracticeGuideline on local & locoregional #ProstateCancer:
✅New imaging modalities: Improved diagnosis, staging & risk stratification
✅Updated algorithms: less over-Tx & fewer side-effects
#Oncology #UroOncology #CancerCare #ESMOGuidelines
🔗 https://ow.ly/jwA650XLs1q
✅New imaging modalities: Improved diagnosis, staging & risk stratification
✅Updated algorithms: less over-Tx & fewer side-effects
#Oncology #UroOncology #CancerCare #ESMOGuidelines
🔗 https://ow.ly/jwA650XLs1q
December 18, 2025 at 2:33 PM
📣 Updated ESMO #ClinicalPracticeGuideline on local & locoregional #ProstateCancer:
✅New imaging modalities: Improved diagnosis, staging & risk stratification
✅Updated algorithms: less over-Tx & fewer side-effects
#Oncology #UroOncology #CancerCare #ESMOGuidelines
🔗 https://ow.ly/jwA650XLs1q
✅New imaging modalities: Improved diagnosis, staging & risk stratification
✅Updated algorithms: less over-Tx & fewer side-effects
#Oncology #UroOncology #CancerCare #ESMOGuidelines
🔗 https://ow.ly/jwA650XLs1q
Developing guidance in #AI is challenging as technology evolves rapidly. ESMO task forces have developed long-lasting recommendations to support the responsible use of AI in #oncology. Read more in the #ESMODailyReporter 📌 https://ow.ly/XonL50XLkVg
#HealthAI #DigitalOncology
#HealthAI #DigitalOncology
December 18, 2025 at 1:20 PM
Developing guidance in #AI is challenging as technology evolves rapidly. ESMO task forces have developed long-lasting recommendations to support the responsible use of AI in #oncology. Read more in the #ESMODailyReporter 📌 https://ow.ly/XonL50XLkVg
#HealthAI #DigitalOncology
#HealthAI #DigitalOncology
📢 Applications open for the #MCCRworkshop!
A week-long workshop to master #ClinicalTrialDesign & learn from global experts.
🔗 Apply now: https://ow.ly/gV7t50XHtgU
📅 13–18 June 2026
✅ Apply by 30 January #ClinicalTrial #ClinicalResearch
A week-long workshop to master #ClinicalTrialDesign & learn from global experts.
🔗 Apply now: https://ow.ly/gV7t50XHtgU
📅 13–18 June 2026
✅ Apply by 30 January #ClinicalTrial #ClinicalResearch
December 18, 2025 at 8:00 AM
📢 Applications open for the #MCCRworkshop!
A week-long workshop to master #ClinicalTrialDesign & learn from global experts.
🔗 Apply now: https://ow.ly/gV7t50XHtgU
📅 13–18 June 2026
✅ Apply by 30 January #ClinicalTrial #ClinicalResearch
A week-long workshop to master #ClinicalTrialDesign & learn from global experts.
🔗 Apply now: https://ow.ly/gV7t50XHtgU
📅 13–18 June 2026
✅ Apply by 30 January #ClinicalTrial #ClinicalResearch
Although the IMbrave152/SKYSCRAPER-14 trial found that adding tiragolumab to 1L atezo + bev did not improve PFS, other studies are under way to evaluate whether additional checkpoint inhibition might still improve outcomes.
#ESMODailyReporter: https://ow.ly/Bfy950XGUCF
#ESMO25
#ESMODailyReporter: https://ow.ly/Bfy950XGUCF
#ESMO25
December 17, 2025 at 2:25 PM
Although the IMbrave152/SKYSCRAPER-14 trial found that adding tiragolumab to 1L atezo + bev did not improve PFS, other studies are under way to evaluate whether additional checkpoint inhibition might still improve outcomes.
#ESMODailyReporter: https://ow.ly/Bfy950XGUCF
#ESMO25
#ESMODailyReporter: https://ow.ly/Bfy950XGUCF
#ESMO25
👉 Don’t miss ESMO Sarcoma and Rare Cancers 2026, from 12 to 14 March 2026 in Lugano. Hear top experts discuss rare tumours and drive global collaboration.
⏰ Early bird rates end 14 January—secure your seat now! #ESMORareCancers26, #esmomeetings
🔗 buff.ly/vMkriyK
⏰ Early bird rates end 14 January—secure your seat now! #ESMORareCancers26, #esmomeetings
🔗 buff.ly/vMkriyK
December 17, 2025 at 10:45 AM
👉 Don’t miss ESMO Sarcoma and Rare Cancers 2026, from 12 to 14 March 2026 in Lugano. Hear top experts discuss rare tumours and drive global collaboration.
⏰ Early bird rates end 14 January—secure your seat now! #ESMORareCancers26, #esmomeetings
🔗 buff.ly/vMkriyK
⏰ Early bird rates end 14 January—secure your seat now! #ESMORareCancers26, #esmomeetings
🔗 buff.ly/vMkriyK
📣 #ESMOBreast26 is more than a meeting: it’s an educational hub where your research connects with practice to spark new collaborations.
⏰ Submit your abstract by 27 January 2026
#esmomeetings
🔗 https://ow.ly/tVP450XpQbk
⏰ Submit your abstract by 27 January 2026
#esmomeetings
🔗 https://ow.ly/tVP450XpQbk
December 17, 2025 at 9:00 AM
📣 #ESMOBreast26 is more than a meeting: it’s an educational hub where your research connects with practice to spark new collaborations.
⏰ Submit your abstract by 27 January 2026
#esmomeetings
🔗 https://ow.ly/tVP450XpQbk
⏰ Submit your abstract by 27 January 2026
#esmomeetings
🔗 https://ow.ly/tVP450XpQbk
📣 All #ESMOImmuno25 congress sessions with speaker permission are now online for registered delegates & ESMO members on #OncologyPRO
👉 Watch on demand and stay at the forefront of oncology. #esmomeetings
🔗 https://ow.ly/7MwC50XHrLB
👉 Watch on demand and stay at the forefront of oncology. #esmomeetings
🔗 https://ow.ly/7MwC50XHrLB
December 16, 2025 at 4:30 PM
📣 All #ESMOImmuno25 congress sessions with speaker permission are now online for registered delegates & ESMO members on #OncologyPRO
👉 Watch on demand and stay at the forefront of oncology. #esmomeetings
🔗 https://ow.ly/7MwC50XHrLB
👉 Watch on demand and stay at the forefront of oncology. #esmomeetings
🔗 https://ow.ly/7MwC50XHrLB
#AI improves pathology precision. A study in ESMO Real World Data & Digital Oncology shows that an AI tool offers reliable PD-L1 scoring, reducing variability & aiding in challenging cases.
Read the commentary @rdienstmann
#ESMODailyReporter #HealthAI https://ow.ly/Ea5G50XHiIG
Read the commentary @rdienstmann
#ESMODailyReporter #HealthAI https://ow.ly/Ea5G50XHiIG
December 16, 2025 at 9:00 AM
#AI improves pathology precision. A study in ESMO Real World Data & Digital Oncology shows that an AI tool offers reliable PD-L1 scoring, reducing variability & aiding in challenging cases.
Read the commentary @rdienstmann
#ESMODailyReporter #HealthAI https://ow.ly/Ea5G50XHiIG
Read the commentary @rdienstmann
#ESMODailyReporter #HealthAI https://ow.ly/Ea5G50XHiIG
📣 Registration for #ELCC26 is open! Join us in Copenhagen, 25–28 March, for cutting-edge science and global networking.
⏰ Early rates until 21 Jan.
🔗 https://ow.ly/mAHv50XBJQL
Don’t miss your chance to shape the future of #LungCancer care!
⏰ Early rates until 21 Jan.
🔗 https://ow.ly/mAHv50XBJQL
Don’t miss your chance to shape the future of #LungCancer care!
December 15, 2025 at 2:25 PM
📣 Registration for #ELCC26 is open! Join us in Copenhagen, 25–28 March, for cutting-edge science and global networking.
⏰ Early rates until 21 Jan.
🔗 https://ow.ly/mAHv50XBJQL
Don’t miss your chance to shape the future of #LungCancer care!
⏰ Early rates until 21 Jan.
🔗 https://ow.ly/mAHv50XBJQL
Don’t miss your chance to shape the future of #LungCancer care!
#ICHNO26: 🔔 Best rates until 17 Dec! Secure your place today and save!
🔗 https://ow.ly/MTCC50XHriG
Join us in Seville, 19–21 March, for #CuttingEdgeScience & multidisciplinary collaboration in #HeadAndNeckOncology.
🔗 https://ow.ly/MTCC50XHriG
Join us in Seville, 19–21 March, for #CuttingEdgeScience & multidisciplinary collaboration in #HeadAndNeckOncology.
December 15, 2025 at 9:30 AM
#ICHNO26: 🔔 Best rates until 17 Dec! Secure your place today and save!
🔗 https://ow.ly/MTCC50XHriG
Join us in Seville, 19–21 March, for #CuttingEdgeScience & multidisciplinary collaboration in #HeadAndNeckOncology.
🔗 https://ow.ly/MTCC50XHriG
Join us in Seville, 19–21 March, for #CuttingEdgeScience & multidisciplinary collaboration in #HeadAndNeckOncology.
The groundbreaking work behind the development of TCR mimics − ‘minibinders’ − is described by Sine Reker Hadrup in her Keynote Lecture at #ESMOImmuno25 and in an Opinion piece in the #ESMODailyReporter #ImmunoOncology
👉 https://ow.ly/jH9x50XHyFI
👉 https://ow.ly/jH9x50XHyFI
December 12, 2025 at 10:20 AM
The groundbreaking work behind the development of TCR mimics − ‘minibinders’ − is described by Sine Reker Hadrup in her Keynote Lecture at #ESMOImmuno25 and in an Opinion piece in the #ESMODailyReporter #ImmunoOncology
👉 https://ow.ly/jH9x50XHyFI
👉 https://ow.ly/jH9x50XHyFI
#ESMOImmuno25: Mature overall survival data from the phase III POD1UM-303/InterAACT-2 #ClinicalTrial confirm the benefits of retifanlimab plus chemotherapy in the treatment of advanced squamous cell #AnalCancer.
Read more #ESMODailyReporter ➡️ https://ow.ly/rPN850XHmSL
Read more #ESMODailyReporter ➡️ https://ow.ly/rPN850XHmSL
December 11, 2025 at 2:30 PM
#ESMOImmuno25: Mature overall survival data from the phase III POD1UM-303/InterAACT-2 #ClinicalTrial confirm the benefits of retifanlimab plus chemotherapy in the treatment of advanced squamous cell #AnalCancer.
Read more #ESMODailyReporter ➡️ https://ow.ly/rPN850XHmSL
Read more #ESMODailyReporter ➡️ https://ow.ly/rPN850XHmSL
#ESMOImmuno25: The next-generation PRAME-directed TCR T-cell therapy, IMA203CD8, showed encouraging activity not only in melanoma, but also in #OvarianCarcinoma and synovial sarcoma in a phase I #ClinicalTrial. Find out more in the #ESMODailyReporter ➡️ https://ow.ly/m30F50XHmHM
December 11, 2025 at 1:10 PM
#ESMOImmuno25: The next-generation PRAME-directed TCR T-cell therapy, IMA203CD8, showed encouraging activity not only in melanoma, but also in #OvarianCarcinoma and synovial sarcoma in a phase I #ClinicalTrial. Find out more in the #ESMODailyReporter ➡️ https://ow.ly/m30F50XHmHM
#ESMOImmuno25: Encouraging data reported with the PD-L1/TGF-β-targeting bifunctional fusion protein, SHR-1701, added to first-line CAPOX in an analysis of patients with #GastricCancer and high-risk features. More info in the #ESMODailyReporter ➡️ https://ow.ly/WF1450XHmqY
December 11, 2025 at 12:30 PM
#ESMOImmuno25: Encouraging data reported with the PD-L1/TGF-β-targeting bifunctional fusion protein, SHR-1701, added to first-line CAPOX in an analysis of patients with #GastricCancer and high-risk features. More info in the #ESMODailyReporter ➡️ https://ow.ly/WF1450XHmqY
#ESMODailyReporter: Jon Lim, MRCP PhD discusses the use of single-cell spatial transcriptomics and proteomic profiling to dissect why #immunotherapy works in some tumours but not others, highlighting neoadjuvant studies at #ESMOImmuno25 #ImmunoOncology
➡️ https://ow.ly/kwgt50XGX4M
➡️ https://ow.ly/kwgt50XGX4M
December 10, 2025 at 4:12 PM
#ESMODailyReporter: Jon Lim, MRCP PhD discusses the use of single-cell spatial transcriptomics and proteomic profiling to dissect why #immunotherapy works in some tumours but not others, highlighting neoadjuvant studies at #ESMOImmuno25 #ImmunoOncology
➡️ https://ow.ly/kwgt50XGX4M
➡️ https://ow.ly/kwgt50XGX4M
#ESMOImmuno25 Awardee, Ignacio Melero, discusses how current #immunotherapy can be improved upon with the use of synergistic approaches including combination therapies and targeting resistance mechanisms. Full interview in the #ESMODailyReporter 👉 https://ow.ly/bgun50XGRUt
December 10, 2025 at 2:32 PM
#ESMOImmuno25 Awardee, Ignacio Melero, discusses how current #immunotherapy can be improved upon with the use of synergistic approaches including combination therapies and targeting resistance mechanisms. Full interview in the #ESMODailyReporter 👉 https://ow.ly/bgun50XGRUt
👉 #ESMOImmuno25: A. Marabelle, I.M. Svane and S. Quezada welcome you to the ESMO Immuno-Oncology Congress 2025, an international event to explore the science driving the next generation of cancer care.
#esmomeetings
🔗 buff.ly/jCNSjtl
#esmomeetings
🔗 buff.ly/jCNSjtl
December 10, 2025 at 11:15 AM
👉 #ESMOImmuno25: A. Marabelle, I.M. Svane and S. Quezada welcome you to the ESMO Immuno-Oncology Congress 2025, an international event to explore the science driving the next generation of cancer care.
#esmomeetings
🔗 buff.ly/jCNSjtl
#esmomeetings
🔗 buff.ly/jCNSjtl
🌍 Uniting the Asia-Pacific oncology community: 4,550+ participants, 170+ speakers, 71 sessions, 70+ countries & 940+ abstracts.
🙌 ESMO Asia 2025 sets a new record in advancing cancer care in Asia! #ESMOAsia25 #esmomeetings
🔗 https://ow.ly/aiwM50XGitY
🙌 ESMO Asia 2025 sets a new record in advancing cancer care in Asia! #ESMOAsia25 #esmomeetings
🔗 https://ow.ly/aiwM50XGitY
December 10, 2025 at 5:00 AM
🌍 Uniting the Asia-Pacific oncology community: 4,550+ participants, 170+ speakers, 71 sessions, 70+ countries & 940+ abstracts.
🙌 ESMO Asia 2025 sets a new record in advancing cancer care in Asia! #ESMOAsia25 #esmomeetings
🔗 https://ow.ly/aiwM50XGitY
🙌 ESMO Asia 2025 sets a new record in advancing cancer care in Asia! #ESMOAsia25 #esmomeetings
🔗 https://ow.ly/aiwM50XGitY
🙌 To everyone who powered ESMO Asia 2025—thank you! From pioneering science to global collaboration, your contributions shaped an inspiring congress.
📅 See you next year in Singapore, 4–6 Dec 2026! #esmomeetings #ESMOAsia25
🔗 buff.ly/J1q4Zzv
📅 See you next year in Singapore, 4–6 Dec 2026! #esmomeetings #ESMOAsia25
🔗 buff.ly/J1q4Zzv
December 9, 2025 at 8:32 AM
🙌 To everyone who powered ESMO Asia 2025—thank you! From pioneering science to global collaboration, your contributions shaped an inspiring congress.
📅 See you next year in Singapore, 4–6 Dec 2026! #esmomeetings #ESMOAsia25
🔗 buff.ly/J1q4Zzv
📅 See you next year in Singapore, 4–6 Dec 2026! #esmomeetings #ESMOAsia25
🔗 buff.ly/J1q4Zzv
⏰ Tomorrow, 9 December, is the abstract deadline for ESMO Sarcoma and Rare Cancers 2026.
👉 The Scientific Co-Chairs highlight how your submission can fuel research progress, spark collaboration & support public health. Act now! #ESMORareCancers26 #esmomeetings
🔗 buff.ly/jqgNWSo
👉 The Scientific Co-Chairs highlight how your submission can fuel research progress, spark collaboration & support public health. Act now! #ESMORareCancers26 #esmomeetings
🔗 buff.ly/jqgNWSo
December 8, 2025 at 8:01 AM
⏰ Tomorrow, 9 December, is the abstract deadline for ESMO Sarcoma and Rare Cancers 2026.
👉 The Scientific Co-Chairs highlight how your submission can fuel research progress, spark collaboration & support public health. Act now! #ESMORareCancers26 #esmomeetings
🔗 buff.ly/jqgNWSo
👉 The Scientific Co-Chairs highlight how your submission can fuel research progress, spark collaboration & support public health. Act now! #ESMORareCancers26 #esmomeetings
🔗 buff.ly/jqgNWSo
#ESMOAsia25: Studies in cancer of unknown primary (#CUP) highlight the need to perform routine comprehensive #GenomicProfiling and then provide access to the appropriate #TargetedTherapy. Find out more in the #ESMODailyReporter ➡️https://ow.ly/sK6H50XF5t7
December 7, 2025 at 11:05 AM
#ESMOAsia25: Studies in cancer of unknown primary (#CUP) highlight the need to perform routine comprehensive #GenomicProfiling and then provide access to the appropriate #TargetedTherapy. Find out more in the #ESMODailyReporter ➡️https://ow.ly/sK6H50XF5t7